Clinical trial
Post-Marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ozempic®. A Multi-centre, Open-label, Non-interventional Post-marketing Study to Investigate the Long-term Safety and Effectiveness of Ozempic® (Semaglutide) in Japanese Patients With Type 2 Diabetes Mellitus Under Normal Clinical Practice Condition
NCT04469855 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Post-Marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ozempic®. A Multi-centre, Open-label, Non-interventional Post-marketing Study to Investigate the Long-term Safety and Effectiveness of Ozempic® (Semaglutide) in Japanese Patients With Type 2 Diabetes Mellitus Under Normal Clinical Practice Condition
- Lead sponsor
- Novo Nordisk A/S
- Phase
- Observational
- Overall status
- Completed
- Start date
- July 27, 2020
- Completion date
- May 12, 2025
- Enrollment
- 3,217 (actual)
- Sites
- 414
Conditions
As the registry lists them; a condition with its own page is linked.